Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus
about
Approved Antiviral Drugs over the Past 50 YearsHIV infection and bone disease.When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank.Long-acting slow effective release antiretroviral therapy.Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.Pharmaceutical characterization of novel tenofovir liposomal formulations for enhanced oral drug delivery: in vitro pharmaceutics and Caco-2 permeability investigationsRilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments.Bone Loss in HIV Infection.Complications of Treatment in Youth with HIV.Tenofovir Alafenamide.Drug interactions in HIV treatment: complementary & alternative medicines and over-the-counter products.Single-Tablet Regimens for the Treatment of HIV-1 Infection.Tenofovir Alafenamide: A Review in Chronic Hepatitis B.Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.Bifunctional aryloxyphosphoramidate prodrugs of 2'-C-Me-uridine: synthesis and anti-HCV activity.Protease inhibitor monotherapy was non-inferior and cost-effective as maintenance therapy compared to triple therapy in viral load suppressed patients with HIV-1 infection.Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination Protects Macaques From Rectal Simian/Human Immunodeficiency Virus Infection.Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque modelSynthetic Approaches for the Preparation of Phosphoramidate Prodrugs of 2'-Deoxypseudoisocytidine.Long-Acting HIV Treatment and Prevention: Closer to the Threshold.Nucleoside/nucleotide reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signalling in endothelial cells.Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy.Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells.Synthesis and anti-HCV activity of a series of β-d-2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs.Hepatitis in AIDS patients.Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.Role of tenofovir alafenamide in the jungle of antiretroviral prescription.Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection.Flexibility-Not just for yoga anymore!A competitive lateral flow assay for the detection of tenofovir.Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?How to Control HTLV-1-Associated Diseases: Preventing de Novo Cellular Infection Using Antiviral Therapy.Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses.Incidence and predictors of tenofovir disoproxil fumarate-induced renal impairment in HIV infected Nigerian patients.Harnessing nanostructured systems for improved treatment and prevention of HIV diseaseDarunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
P2860
Q27755387-10D3032A-934E-4FE8-8FBE-DAB8EA0365E8Q30249771-0238358C-C423-4B3A-A569-0F58BDC7CC2BQ33765196-41D040AF-022C-41B9-BFDB-280874C46FCAQ36262152-A0406F7A-55A3-49CC-9F9D-C65FEA9B436FQ36275141-E3F01669-6D2A-42C7-8447-04609A02888DQ37669191-0B36D3C2-6486-4C8E-9DA2-7487F3ABE85EQ38802093-BFAA8F57-9C5B-481D-BE95-283E127B7721Q38821304-AA51CA78-E146-42BC-B954-7468E1FB5C83Q38835028-FD76D84D-F2CE-43BD-9484-6CB518B3E7DCQ38846571-C228E386-09B0-4DE8-A7C8-DB16C29C4072Q38910661-B01E8BF0-BD32-4219-AF28-DEC2F3709040Q38974893-F643C6B7-45B6-4759-B155-F39B7C6B98F2Q39022885-127AC6E7-6EE9-41E2-993E-A4CD9C4E3386Q39298139-54153FB7-EAB8-4277-9DD3-053FF3F712B9Q39371494-5746BEDC-7E0B-4DE1-BAAA-24E8C5494302Q39426047-25B9646C-3EDF-43D5-8DAA-97CCA18E69A1Q40401616-970A39C5-526C-47CE-AC21-52C5E4007A6FQ40514370-FE2FF19D-F88D-4F04-8D13-F09A88E87C5FQ40561708-F6D9BFE9-3B60-47AC-AF2C-09130C1F8C70Q40597405-AB522B4D-A918-4AA0-8F57-CB3078491653Q41923505-0BC6E922-A3DD-4E88-AF29-8EC0BF8FBDD0Q42196760-62BBE979-CBB8-4C90-966B-9A58921DE379Q42334096-4D7781A5-1368-4E6E-BA79-02593A0C8001Q46130631-AABB7EFF-833B-498A-B4F7-669AF055AF6FQ47142298-32BB5F4C-CB93-422A-A7FF-C02D09E88AF7Q47151161-1A5B55CF-6C26-4E42-BE7A-E31266995B4EQ47601762-E1387810-DB96-44F4-AE34-442AB8704CA2Q48191650-AD3FF7E9-321D-4AA2-8C46-577B46674B54Q50059498-DCA4E1BA-543F-401D-A2B3-C8030D77E78EQ50080891-5BD359D6-A14B-4F4B-97A7-6D56AF9E9501Q52664377-12712F40-9CAF-4C08-8943-E51D4C2572DFQ52691809-BAC9A826-74E0-4EF9-B676-5A1379A566BEQ53702307-3F58CCCC-7EF9-4CF3-81C1-5F83EADC5619Q54230654-A6E3E39F-F037-4567-A03B-87759A5EA973Q54246489-289EF796-EBEE-4D97-B932-0FFB8DEACFBFQ54256710-11137B94-BFE0-4227-8428-BD286847E231Q55303657-4DD44CC2-7148-41EF-8052-B286879D90D2Q56992437-9B403419-455A-4194-BDB0-D9AE6A47C454Q59126145-1F28E774-EB9C-4A26-BE63-DFDBD63A58E4
P2860
Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Tenofovir alafenamide: A novel ...... f Human Immunodeficiency Virus
@ast
Tenofovir alafenamide: A novel ...... f Human Immunodeficiency Virus
@en
Tenofovir alafenamide: A novel ...... f Human Immunodeficiency Virus
@nl
type
label
Tenofovir alafenamide: A novel ...... f Human Immunodeficiency Virus
@ast
Tenofovir alafenamide: A novel ...... f Human Immunodeficiency Virus
@en
Tenofovir alafenamide: A novel ...... f Human Immunodeficiency Virus
@nl
prefLabel
Tenofovir alafenamide: A novel ...... f Human Immunodeficiency Virus
@ast
Tenofovir alafenamide: A novel ...... f Human Immunodeficiency Virus
@en
Tenofovir alafenamide: A novel ...... f Human Immunodeficiency Virus
@nl
P1433
P1476
Tenofovir alafenamide: A novel ...... f Human Immunodeficiency Virus
@en
P2093
Marshall W Fordyce
Michael J M Hitchcock
P356
10.1016/J.ANTIVIRAL.2015.11.009
P407
P577
2016-01-01T00:00:00Z